They were and did. NP has stated several times and again during today’s call that the FDA needed to relax the enrollment criteria to increase enrollment. For the P2 CD10 trial it was because most M/M patients were not being admitted to the hospitals, thus it was difficult for the doctors to enroll patients. Previously they changed the trial protocol to update/clarify screening criteria to include patients treated with remdesivir along with other changes. Dr. Yang and Dr. Harish were two of the largest enrollment doctors for eIND patients and also for both the P2 and P3 trials.